Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

UBS Keeps a Buy Rating on Celgene (NASDAQ:CELG) and $146.0 Target

UBS Analyst Rating Change Celgene NASDAQ:CELG

Celgene (NASDAQ:CELG) Rating Kept

In a note sent to clients and investors on Friday morning, Celgene (NASDAQ:CELG) Stock had its Buy Rating restate by stock analysts at UBS. They currently have a $146.0 PT on company. UBS’s target means a potential upside of 7.38 % from the company’s last stock close.

NASDAQ:CELG is currently trading -0.88% lower at $135.96 as of 4:03 AM New York time. Celgene’s stock is 0% over the last 200 days. It has underperformed the S&P 500 Index, which has surged 6.00% over the same time.

According to data compiled by Thomson Reuters, Celgene (NASDAQ:CELG)’s stock is covered by 22 equity analysts across the Street, with 1 analysts giving it a Sell rating, 20 a Buy rating, while 4 consider it a Hold. The 12-month consensus target price for the stock is $136.82, which reflects an upside potential of 0.63% over the current price.

Institutional Ownership

Oaktop Capital Management Ii L.P. had the biggest stake with ownership of 2.08 million shares as of Q2 2015 for 50.82% of the long stock exposure. Birchview Capital Lp is another quite bullish institutional investor who is having 777,051 shares of Celgene or 47.4% of their long stock exposure. Moreover, Selkirk Management Llc have 15.93% of their long stock exposure invested in the company for 248,250 shares. The Switzerland-based fund Bb Biotech Ag revealed it had bought a stake worth about 12.71% of the institutional investor’s stock portfolio in Celgene. The New Jersey-based fund Fcg Advisors Llc is also positive about the stock, possessing 3.46 million shares or 11.6% of their long stock exposure.

Celgene (NASDAQ:CELG) Profile

Celgene CorpCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).

Celgene (NASDAQ:CELG) traded down -0.88% on 20 October, hitting $135.96. A total of 96,045 shares of the company’s stock traded hands. This is down from average of 3.98M shares. Celgene has a 52 week low of $96.93 and a 52 week high of $147.17. The company has a market cap of $106.37B and a P/E ratio of 42.28.

Get the latest Celgene (NASDAQ:CELG) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post UBS Keeps a Buy Rating on Celgene (NASDAQ:CELG) and $146.0 Target appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

UBS Keeps a Buy Rating on Celgene (NASDAQ:CELG) and $146.0 Target


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription